Press Releases

Preclinical data highlights AH-001 as potentially compelling targeted dermatology treatment options.

Company’s proprietary drug discovery platform provides unique approach to rationally design bi-functional degraders and molecular glues to have differentiated drug profiles.

After 6 months of close collaboration with our AI and drug design teams in discovery, we have advanced the drug profile...